Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
ADARx Pharmaceuticals, Inc.
90 participants
Apr 2, 2026
INTERVENTIONAL
Conditions
Summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Eligibility
Inclusion Criteria3
- Have a documented diagnosis of HAE (Type I or II)
- Completed Study ADX-324-301
- Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
Exclusion Criteria1
- A negative reaction to study drug in ADX-324-301
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
siRNA duplex oligonucleotide
siRNA duplex oligonucleotide
Locations(48)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07428499